Premium
Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis
Author(s) -
Boncoraglio G.,
Carriero M. R.,
Chiapparini L.,
Ciceri E.,
Ciusani E.,
Erbetta A.,
Parati E. A.
Publication year - 2004
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2004.00802.x
Subject(s) - medicine , hyperhomocysteinemia , methylenetetrahydrofolate reductase , venous thrombosis , risk factor , gastroenterology , stroke (engine) , prospective cohort study , thrombosis , factor v , factor v leiden , population , cohort study , homocysteine , genotype , mechanical engineering , biochemistry , chemistry , environmental health , engineering , gene
Despite the continuous description of new conditions pre‐disposing for cerebral venous thrombosis (CVT), no apparent cause is found in about 30% of cases. Hyperhomocysteinemia (hyper‐Hcy) is an established risk factor for deep venous thrombosis and stroke but has not been clearly associated with increased risk of CVT. We assessed the prevalence of hyper‐Hcy and other thrombophilic risk factors in a population of 26 consecutive patients with non‐pyogenic CVT, by review of a prospectively maintained database. The prevalences of hyper‐Hcy and prothrombin G20210A, factor V G1691A and methylenetetrahydrofolate reductase (MTHFR) C677T mutations in these patients were compared with those in 100 healthy controls and 100 patients with cerebroarterial disease. The prevalence of hyper‐Hcy was greater in patients with CVT (10/26, 38.5%) than healthy controls (13/100; OR 4.18, 95% CI 1.58–11.16) and comparable with that in patients with cerebroarterial disease (42/100). No significant differences were found in the prevalences of prothrombin or MTHFR mutation. No factor V mutation was found. Our findings indicate that hyper‐Hcy is associated with an increased risk of CVT. Additional prospective cohort studies on large series of patients are required to clarify the time relationship between hyper‐Hcy and the thrombotic event.